The mechanisms underlying the high levels of hepatitis B virus (HBV) replication that cause hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (e"CHB) are unknown. Impaired anti-HBV immunity, which may be measurable as a relaxation of selection pressure on the virus, is possible. A group of Tongans (n5345) with a chronic HBV infection, including seven with e"CHB, were genotyped at HLA class I. The repertoire of HBV core-gene codons under positive selection pressure was defined by phylogenetic analysis (by using the PAML program) of 708 cloned sequences extracted from the 67 of these 345 subjects with the same repertoire of HLA class I alleles as the seven e"CHB individuals and matched controls (see below). The frequency of non-synonymous mutations at these codons was measured in longitudinal data from 15 subjects. Finally, the number of non-synonymous mutations at these codons was compared in seven groups comprised of one subject with e"CHB and 1-3 HLA class I-matched controls with an inactive, HBeAg-negative chronic HBV infection (e"InD). Nineteen codons in the core gene were under positive selection pressure. There was a high frequency of new non-synonymous mutations at these codons (P,0.0001) in longitudinal data. The mean number of these 19 codons with non-synonymous mutations was lower (P50.02) in HBV from subjects with e"CHB (4.4±0.5 codons per subject) versus those with e"InD (6.4±0.4 codons per subject). There is a subtle relaxation in selection pressure on the HBV core gene in e"CHB. This may be due to impaired antiviral immunity, and could contribute to the high levels of viral replication that cause liver inflammation in this disease.
INTRODUCTION
Chronic hepatitis B virus (HBV) infections usually evolve through three stages (Lok & McMahon, 2007) . Initially the virus avoids the host immune system, probably because of the immune suppressant effects of the viral hepatitis B e antigen (HBeAg) (Milich & Liang, 2003) . This results in high levels of viral replication in the liver, high levels of serum HBeAg and no detectable liver inflammation. The patient has an inactive, HBeAg-positive chronic HBV infection (e+InD) that is also known as the 'immune tolerant' stage of the disease. Immune tolerance to HBV is eventually lost in most patients, for reasons that are unknown. Acquired immunity to HBV antigens becomes detectable in peripheral blood mononuclear cells and when serum levels of HBV-DNA and HBeAg fall, anti-HBeAg antibodies appear in serum, and there is usually evidence of liver inflammation. This process is known as HBeAg seroconversion, and it eventually leads to CD8 + T-cell-mediated suppression of viral replication, clearance of the HBeAg from serum and liver inflammation ceasing. The patient then has an inactive, HBeAg-negative chronic HBV infection (e2InD), and this is also known as the inactive, healthy carrier stage.
There is a subset of patients who do not suppress viral replication at the time immune tolerance is lost. These patients, who can be either HBeAg-positive or HBeAgnegative, develop persistent liver inflammation that is known as chronic hepatitis B (CHB). CHB is associated with a high risk of liver cirrhosis and hepatocellular carcinoma (Lok & McMahon, 2007) , and lifelong treatment with antiviral drugs that suppress replication of the virus is currently required to prevent these sequelae (Lok & McMahon, 2007; Reijnders et al., 2010) . These treatments are expensive, require frequent monitoring and are associated with life-threatening flares of hepatitis because of the emergence of drug-resistant mutations (Lok & McMahon, 2007) . A therapeutic vaccine that suppressed viral replication in these patients could make a valuable contribution to the management of this disease.
This study is focused on the HBeAg-negative form of CHB (e2CHB). Since e2CHB is associated with high levels of viral replication (Lok & McMahon, 2007) , the first step in designing a therapeutic vaccine is to identify the reason(s) that the host immune system is unable to suppress replication of HBV to the levels found in subjects with e2InD. Studies of the cellular immune response to HBV antigens have not convincingly identified any evidence of a defect in HBV-specific immunity in e2CHB relative to e2InD (Boni et al., 2007; Günther, 2006) . However it is likely that such defects exist (Chin & Locarnini, 2003) . In this study, we have tried an alternative method to demonstrate the existence of a defect in HBV-specific immunity in e2CHB.
Subjects with e2InD have more non-synonymous mutations in the HBV core gene than patients with e2CHB (Sendi et al., 2009) . Most of these mutations arise within HBV-infected subjects during (Lim et al., 2007; Wu et al., 2011) and after (Akarca & Lok, 1995; Hannoun et al., 2000) HBeAg seroconversion. However it is not clear whether the increased number of these HBV core gene mutations in e2InD, relative to e2CHB, results from an increase in escape mutations that arise from positive selection pressure, or whether they result from a higher rate of genetic drift owing to a lower effective population size. We have previously used phylogenetic analysis of cloned HBV sequences to measure positive selection pressure on the HBV core gene in subjects with e2InD (Abbott et al., 2010) . In those analyses, we identified core gene codons that were under either HLA class I-restricted selection pressure that might be because of CD8 + T-cells, or non-HLA-restricted selection pressure that was possibly the result of innate immunity. In this study, we have compared the breadth and the strength of positive selection pressure on HBV core-gene codons in HLA class I-matched patients with e2CHB and e2InD. The first stage of the study was to identify all the codons in the core gene that are commonly under positive selection pressure in 67 subjects with a chronic HBV infection, who were selected to contain the same repertoire of HLA class I alleles as the matched e2InD and e2CHB groups. The second stage of the study was to demonstrate an increase in frequency of nonsynonymous mutations at these codons over time, using within-subject, longitudinal data. The third stage was to compare the repertoires of non-synonymous mutations at these positively selected codons in the matched e2CHB and e2InD groups.
RESULTS
Selection pressure on the HBV core gene Seven hundred and fifty-two full-length, 1125 bp clones containing the HBV core gene were obtained from the 67 subjects with a chronic HBV infection described in Table 1 . The mean±SD number of clones per subject was 11.22±4.69, and the range was 5-29 clones per subject. Forty-four clones containing nonsense mutations in the core-gene sequence were discarded, and the remaining 708 core-gene sequences were analysed in PAML. Maximumlikelihood analysis predicted that 68.3 % of the 183 codons in the core gene were under negative selection (v50.09), 21.2 % were under neutral selection (v51.00) and 10.5 % were under positive selection (v53.48). Site-by-site analysis identified 41 codons that were under neutral selection (data not shown). The 19 codons that were under positive selection (v.2.0) are listed in Table 2 . The mean percentage of subjects whose HBV had non-synonymous mutations at each of the 19 codons was higher in e2InD than in either e+InD (+26±3 %, P,0.0001) or e2CHB (+12±5 %, P50.03). The mean percentage of subjects whose HBV had non-synonymous mutations at each of the 19 codons was higher in e2CHB than in e+InD (+13±6 %, P50.04). There were only two codons in which the frequency of non-synonymous mutations differed in HBV DNA extracted from the e2InD and e2CHB groups. The frequency of subjects whose HBV had non-synonymous mutations at Ile97 was higher in e2InD than e2CHB (26/46 versus 1/7, P50.05) and the frequency of subjects whose HBV had non-synonymous mutations at Arg151 was lower in e2InD than in e2CHB (8/46 versus 4/7, P50.04).
Evolution of non-synonymous mutations at positively selected core gene codons Non-synonymous mutations in the 19 positively selected codons were identified in 107 HBV clones (mean±SD 57.1±2.3, range 3-11 clones/subject) extracted from an initial serum sample (baseline) taken from 15 HBeAgpositive subjects, and 103 clones (mean±SD56.9±1.7, range 3-8 clones/subject) extracted from a serum sample taken a mean of 5.0±0.5 years later. The number of clones per subject was never larger at the second time point, so increases in the number of detected mutations with time were not due to more clones being sequenced at the second time point. The numbers of subjects from whom at least one clone with a non-synonymous mutation at each of these codons was identified at either both time points, the first time point only or the second time point only are shown in Table 3 Table 1 . Gender, mean age and mean maximum serum alanine transaminase (ALT) levels of the three groups of subjects selected because their HLA class I genotypes were comprised of the HLA-A, HLA-B and HLA-C alleles found in the study subjects described in Table 5 The mean ALT levels are the mean of the highest ALT level recorded for each subject by the New Zealand Hepatitis B Screening Programme. The numbers of each HLA-A, HLA-B and HLA-C allele in each group are shown. e+InD, Inactive, HBeAg-positive chronic HBV infection; e2InD, inactive, HBeAg-negative chronic HBV infection; e2CHB, HBeAg-negative chronic hepatitis B. Table 2 . Core-gene codons under positive selection pressure (v.2) in HBV from 14 e+InD, 46 e"InD and 7 e"CHB subjects Posterior probability is the probability that the codon is assigned to this category, given the data and estimated parameters: *, P.0.95; **, P.0.99.
Codon
Wild-type amino acid Posterior probability DThe number (percentage) of subjects with at least one clone with a non-synonymous mutation.
seroconvert (7/124). The frequency of new non-synonymous mutations in the 19 positively selected codons (29/253) was higher (P50.003) than the frequency of new nonsynonymous mutations in the 41 codons that were under neutral selection (35/598). Subjects who seroconverted had a higher frequency of non-synonymous mutations in the 19 positively selected codons in the baseline sample than the subjects who did not seroconvert (23/152 versus 9/133, respectively, P50.04).
Comparison of non-synonymous mutations at positively selected codons in HLA class I-matched groups with e"CHB and e"InD
Although the subjects in the three groups described in Table 1 had almost identical repertoires of HLA class I alleles, the frequencies of these alleles in the groups were not the same. It is possible that the difference in selection pressure on the core gene between e2CHB and e2InD groups was because of differences in HLA class I-mediated selection pressure. To exclude this possibility, we conducted a paired analysis of selection pressure in patients with e2CHB who were individually matched at HLA class I to subjects with e2InD. The data in Table 4 compares the number of the 19 positive selection pressure-vulnerable codons that contained non-synonymous mutations in each e2CHB subject with the mean number observed in the HLA class I-matched e2InD controls. The number of clones sequenced from each subject (mean±SD510.1±4.3, range 6-18 clones per subject) and the number of clones containing a non-synonymous mutation at each codon are shown in Supplementary Table S1 (available in JGV Online). The number of clones from each e2CHB subject was always larger than the mean number from the matched group of e2InD subjects, ensuring that the differences between the pairs were not due to there being more opportunities for mutations to be detected in e2InD. In the paired analysis, the mean number of the 19 selection pressure-vulnerable codons containing a non-synonymous mutation/subject in each of the seven groups of e2InD was higher (+2.0±0.5 codons per HLA-matched group, P50.02) than in each matched e2CHB subject. There was no difference in the number of codons for which selection pressure resulted in fixation of non-synonymous mutations between e2InD and e2CHB (20.4±0.7 fixed mutations per HLA-matched group, P50.53). There were no significant differences in the frequency of subjects whose HBV had non-synonymous mutations at codons Ile97 and Arg151 between the matched groups.
DISCUSSION
The selection for non-synonymous mutations in HBV ORFs following positive selection pressure from antiviral drugs , immunoprophylaxis (Hsu et al., 2004) and CD8 + T-cells (Bertoletti et al., 1994; Whalley et al., 2004 ) is well described. These substitutions generally arise in the amino acids that are specifically recognized by the agent that exerts a selective pressure that favours Core-gene mutations in chronic hepatitis B change and the development of these substitutions is associated with increased viral replication. Computer programs such as PAML are able to classify mutations into those that are the result of selection pressure and those that are most likely to be the result of neutral evolutionary processes. This creates an opportunity to measure the level of selection pressure on a viral gene in the absence of knowledge of the specific mechanisms involved.
In the first stage of this project, we identified 19 codons in the HBV core gene that fulfilled the PAML criteria for being under positive selection pressure in subjects with a chronic HBV infection. In the second stage, we addressed the issue of whether non-synonymous mutations in these codons arise within patients during the course of a chronic HBV infection; the alternative possibility being that they are present in HBV at the time of initial infection having arisen in previously infected subjects. This issue is important, because it is necessary to demonstrate the evolution of mutations within subjects in order to consider the possibility that these mutations might be the direct result of immunemediated selection pressure within those subjects. The data clearly show that new non-synonymous mutations occur at a higher rate in the 19 positively selected codons than in codons under neutral selection. The rate of new nonsynonymous mutations in these codons in the group of subjects that did not seroconvert was 7 per 35 person-years. This is high enough to account for the nine nonsynonymous mutations that were already present at these sites in the baseline samples from these seven 30-year-old subjects, who probably have 100-200 person-years of chronic HBV infection between them. The rate of new non-synonymous mutations in the group that did seroconvert was 22 per 40 person-years. This is high enough to account for the 23 non-synonymous mutations that were already present at these sites in these eight 40-year-old subjects at the time of their first serum sample, since they are likely to have more than 200 years of chronic HBV infection between them. These results are consistent with either the de novo accumulation of substitutions over time or with the possibility that these variants existed in very low numbers at the initial time point and were selected for in the presence of immune pressure. Finding the highest frequency of new non-synonymous mutations in the group who experienced HBeAg seroconversion is consistent with previously published data (Akarca & Lok, 1995) . This finding is also consistent with the possibility that these changes are a response to changes in host immunity, as the process of HBeAg seroconversion is believed to be associated with activation of the immune response to HBV (Liaw et al., 2008; Lok et al., 2001) . The higher frequency of nonsynonymous mutations in the baseline sample of subjects who seroconverted is also of interest, as it suggests that HBV is responding to the changes in immunity that precede the HBeAg seroconversion event.
Patients with e2CHB have high levels of viral replication relative to subjects with e2InD. This could be because of a failure of the host immune system to put selection pressure on HBV in these patients or to an increased ability of HBV in these patients to escape from selection pressure through the development of compensatory mutations (Crawford et al., 2007) . A failure to put selection pressure on HBV should result in either or both of: (a) a reduced number of codons showing evidence of selection pressure and (b) a reduced frequency of escape mutations achieving fixation. An increased ability to escape selection pressure should result in an increased number of codons showing evidence of selection pressure, an increased frequency of escape mutations achieving fixation or a different repertoire of codons being under selection pressure. Our data show that HBV from subjects with e2CHB have a reduced number of codons in the core gene that are under selection pressure relative to HBV from subjects with e2InD, although both groups had more selection pressure on the HBV core gene than HBVs from the e+InD group. This is consistent with the hypotheses that the HBeAg is responsible for suppressing the immune response to HBV and that loss of the HBeAg allows activation of this response and the generation of selection pressure on HBV genes. The frequencies with which non-synonymous mutations reached fixation and the repertoires of codons under selection pressure were similar in the two groups. Thus, our data are most consistent with the possibility that HBVs from both e2CHB and e2InD subjects are placed under an increase in selection pressure at the time of HBeAg seroconversion. However there is probably a subtle decrease in the number of immune mechanisms that put selection pressure on the HBV core gene in e2CHB relative to e2InD (see next paragraph) and this may contribute to the high levels of HBV replication that cause liver inflammation. Identification of these immune mechanisms should be worthwhile as they may give clues to immune mechanisms that might be targets of a therapeutic vaccine for e2CHB.
It is only possible to speculate about the mechanisms that failed to put selection pressure on the HBV core gene in the e2CHB patients. There is good evidence that the CD8 + Tcell response to the core aa 18-27 peptide contributes to viral suppression in HLA-A*02 positive subjects (Bertoletti et al., 1994) . There is weaker evidence of suppression mediated by CD8 + T-cells responding to core peptides presented by HLA-A*11 (Missale et al., 1993) , HLA-A*2402 (Sobao et al., 2001) , HLA-B*4001 and HLA-B*5602 (Abbott et al., 2010) . It will be difficult to conclusively demonstrate that a subtle defect in CD8 + Tcell responses to HBV peptides contributes to the risk for e2CHB patients until the whole repertoire of common HLA class I-HBV-peptide interactions in humans has been defined. Similarly there is now evidence that the human innate immune system is able to detect and respond to HBV (Durantel & Zoulim, 2009; Lucifora et al., 2010; Visvanathan et al., 2007) . It is possible that innate immunity contributes to positive selection pressure on the HBV core gene that is not HLA class I restricted (Abbott et al., 2010) . As with CD8
+ T-cells, it will be difficult to demonstrate that a lack of innate immune system-driven selection pressure contributes to the high level of viral replication in e2CHB until the molecular basis underlying innate detection of the virus is known. Other contributors to variability in the immune response to HBV that might contribute to the risk for e2CHB include age of infection (Publicover et al., 2011) , age of HBeAg seroconversion (Liaw, 2009) , ethnic variability within the Tongan population (Abbott et al., 2006a) and host genetics (Abbott et al., 2006b; Hirankarn et al., 2007; Lin et al., 1989; Wu et al., 2010) .
There are a number of limitations to these conclusions. First, there were only seven patients with e2CHB, and random sampling error could have had an influence. The increased level of selection pressure in e2InD subjects may be a false-positive result. Alternatively, it is surprising that such a small sample was able to detect such a small difference in positive selection pressure between the e2CHB and e2InD groups, suggesting that random sampling error in this study may have resulted in an underestimate of the true difference. The differences in frequency of subjects whose HBV had non-synonymous mutations at Ile97 and Arg151 found between the groups in the unpaired data are also difficult to assess. These differences were not found in the paired data, and may also be due to random sampling error. HLA class I-mismatching in the unpaired data is another possibility. However, the possibility that they represent a real difference between e2CHB and e2InD cannot be excluded, but will need confirmation in a larger study. Second, it was not possible to obtain perfect matching of all six HLA class I alleles in the e2CHB and e2InD groups, and this may have resulted in an overestimation of the difference between the groups. The most significant mismatch was the higher frequency of the HLA-A*0206 allele in the e2InD group. This is one of the HLA-A*02 supertype family alleles that can present the core 18-27 peptide from the HBV core gene of HBV of genotypes A and D (Bertoletti et al., 1994; del Guercio et al., 1995) , resulting in selection pressure on the serine amino acid encoded by codon 21 (Bertoletti et al., 1994) . There were two HLA-A*0206-positive, e2InD subjects infected with a genotype D virus in this study (Table 5 , groups 5 and 6) and both had selection pressure at Ser21. However reanalysing the dataset without the Ser21 data from these two subjects still results in a statistically significant (P50.03) difference between the e2InD and e2CHB groups. All the other subjects with selection pressure at Ser21 were positive for the HLA-B*5602 allele, and this association has been previously reported (Abbott et al., 2010) . Finally, it is possible that conclusions drawn from a study of Tongan subjects may not be generalizable to other ethnic groups.
There are a number of potential sources of bias in the PCR amplification and cloning of HBV genomes from serum samples. In subjects with e2InD, these arise from the accumulation of mutations and the low serum HBV-DNA concentrations. The increased number of mutations that occur in e2InD can result in the loss of primer binding sites on some haplotypes and possibly in differences in amplification efficiency between different haplotypes. However, the HBVs in the Tongan population are homogeneous relative to other populations and we have identified highly conserved PCR primer binding sites in these HBVs that bind to positions that we know, from sequencing these sites using a different clone (Abbott et al., 2010) , have negligible rates of nucleotide mutation in HBVs from Tongan e2InD subjects, especially in the 39 pentamer-binding site. A relative loss of amplification efficiency caused by accumulation of specific mutations is a problem that cannot be controlled for, but there is no reason to believe that this is a more significant problem in e2CHB than in e2InD. Amplifying HBV from samples with a low HBV-DNA concentration can result in nonrandom amplification of viral haplotypes. However, this is only a problem when multiple clones are selected from one PCR. In this study, we only selected one clone from each PCR, and thus we know that every HBV sequence we have reported comes from a different serum virus. In all cases, the impact of these sources of bias should be to reduce the detected variability in the HBV genome in subjects with e2InD relative to e2CHB. This is unlikely to result in the increased level of positive selection pressure on HBV found in the e2InD subjects in this study, and may have resulted in an underestimation of the difference between the groups.
In summary, these data demonstrate a subtle relaxation in positive selection pressure on the HBV core gene in patients with e2CHB. This might be because of weaker immune surveillance, and might contribute to the high levels of viral replication that cause the liver inflammation seen in this disease. The full repertoire of host antiviral immune mechanisms that recognize HBV core-gene antigens needs to be defined, as some of these may be useful targets of a therapeutic vaccine for HBeAg-negative chronic hepatitis B.
METHODS
Subjects. The New Zealand Hepatitis B Screening Programme monitors 1439 Tongan adults with a chronic HBV infection at 6-12 monthly intervals and checks HBeAg status, serum ALT levels and afetoprotein (AFP). We serially recruited 345 of these subjects into this study at the time of a routine blood test. An extra 3 ml of serum was taken for HBV-DNA analyses, and genomic DNA was extracted from PBMC for HLA class I genotyping, which was performed on all subjects. None of these patients were known to have chronic hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infections. None of these patients had clinical evidence of primary immunodeficiency, lymphoma or leukaemia or were taking immunosuppressant medication. All subjects gave written consent, and the study was approved by the Northern X Regional Ethics Committee of the New Zealand Ministry of Health.
Eight HBeAg-negative subjects from this group with at least two raised serum ALT levels (.60 IU l
21
) 3 months apart were referred for specialist assessment within a period of 3 months. They were diagnosed as having e2CHB on the basis of persisting raised ALT levels at the time of specialist assessment, a raised HBV-DNA titre and appropriate changes on liver biopsy (Scheuer, 1970) . None had previously taken antiviral therapy, none had HCV (Ampliprep and Taqman HCV Test; cobas), hepatitis delta virus (Yamashiro et al., 2004) or HIV (Ampliprep and Taqman HIV-1 Test V2.0; cobas) infections, and none had a raised AFP level or clinical or laboratory evidence of immune deficiency or autoimmune disease. In seven of the eight subjects, the HBV-DNA titre (cobas Amplicor or Roche cobas Ampliprep, and cobas Taqman Systems) was .200 000 copies ml
, and in one subject with liver cirrhosis (case 5) the HBV-DNA titre was 24 000 copies ml 21 . All subjects had at least Scheuer stage 2 fibrosis ( Table 5) . The maximum ALT level shown for the e2CHB subjects in Table 5 is the higher of the two raised values obtained at the screening before specialist referral. HBV-DNA for cloning analyses was extracted from one of these two screening sera.
We identified 67 subjects (from the recruited group of 345 subjects) who had an HLA class I genotype comprising the alleles that were present in the seven e2CHB patients and HLA class I-matched e2InD subjects shown in Tables 5 and 6 . The clinical characteristics of this group of subjects are shown in Table 1 . Fourteen of these subjects had an inactive, HBeAg-positive chronic HBV infection (e+InD) and 46 had an inactive, HBeAg-negative chronic HBV infection (including the 15 e2InD subjects in Table 5 ) at the time serum was taken for HBV-DNA analysis. The seven subjects with e2CHB were also included. The criteria for inclusion in the e+InD group were: having at least two serum samples a minimum of 6 months apart that were positive for hepatitis B surface antigen (HBsAg), positive for HBeAg and that did not meet the criteria for referral to a hepatology clinic (consecutive ALT levels .60 IU l 21 or AFP .10 mg l
). The criteria for inclusion in the e2InD group were having at least two serum samples a minimum of 6 months apart that were positive for HBsAg, were negative for HBeAg and that did not meet the criteria for referral to a hepatology clinic (consecutive ALT levels .60 IU l 21 or AFP .10 mg l
). The purpose of studying positive selection pressure on the core gene in this diverse group of subjects was to identify every core gene codon that commonly comes under positive selection pressure in Tongan subjects with this repertoire of HLA class I alleles.
A separate group of 15 subjects with e+InD was then selected for a longitudinal study. Eight of these subjects, aged 40.6±3.0 years at baseline, underwent spontaneous HBeAg seroconversion before giving a follow up serum sample at 5.1±0.5 years after the baseline sample. Seven of these subjects, aged 31.1±5.2 years at baseline, remained HBeAg-positive for 4.9±0.5 years before giving their follow up sample.
Twenty-five e2InD subjects from the cohort of 345 subjects were identified who could be individually matched to seven of the eight e2CHB subjects at both HLA-B alleles, and at either three or four HLA-A and HLA-C alleles. The HBV core gene could be PCR amplified from 15 of these 25 e2InD subjects. Thus, there were seven groups of subjects containing one e2CHB case matched to between one and three e2InD controls (Table 5 ). Seven e2InD subjects were matched for all six HLA class I alleles and eight e2InD subjects were matched for five of six alleles (Table 6 ). The mean age of the e2CHB group was 51.4±3.9 years (mean±SEM) and the mean age of the e2InD group was 48.3±3.1 years. The maximum ALT level of the e2InD subjects shown in Table 5 is the highest of a minimum of four ALT levels measured between four and nine years of follow up.
Cloning and sequencing HBV. This study describes the results of cloning and sequencing a 1125 bp sequence running from bases 1633-2757 (numbering taken from GenBank sequence X75656) of the HBV genome that includes the entire C ORF, the initial 451 bp of the P ORF and the terminal 203 bp of the X ORF. The rationale for choosing the PCR primers, the PCR conditions and the cloning and sequencing strategies for genotype C HBVs have been described in detail in a previous publication (Abbott et al., 2010) . The only difference for subjects with a genotype D HBV was the position of the reverse primer (59-GAATATGGTGACCCACAAAATGA-39) which binds to positions 2827-2805 of GenBank sequence AF121240 and is highly conserved in Tongans. Only one clone from each PCR was sequenced and analysed.
Phylogenetic analyses of HBV clones. The phylogenies of the viruses obtained from the different patients were constructed by using Table 5 . Age (years), sex (M/F) and maximum serum ALT level (IU l "1 ) of subjects comprising the seven HLA class I-matched groups of subjects with either e"CHB or e"InD The Scheuer grade (G) and stage (S) of the liver biopsy are also shown for e2CHB subjects. (Guindon et al., 2004) . The PAML program (Yang et al., 2005) was then used to estimate the overall proportion of codons in the whole alignment that were likely to be under positive, neutral or negative selection pressures (PAML model 2A), and an estimate of the mean value of the ratio of non-synonymous to synonymous nucleotide substitution rates (v) was made for each of the three categories. The posterior probability of positive selection pressure at each codon was then calculated using the Bayes empirical Bayes criterion. Posterior probability is the probability that the codon is assigned to the positive selection pressure category, given the observed sequence data and the estimated parameters (including v).
Calculation of the rate and the frequency of new nonsynonymous mutations. The rate of new non-synonymous mutations in the longitudinal data was calculated as the sum of the number of non-synonymous mutations present at the second time point only (Table 5 ) divided by the total number of years between the samples in the whole group of subjects. The frequency of new mutations was the number of mutations at the second time point only divided by the number of wild-type codons at the first time point (i.e. the number of codons at the first time point that were available for mutation). Mismatches between e2CHB and e2InD are indicated by boldface type.
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